We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byNatalie Kearney
Modified over 5 years ago
Sibbing D, et al. J Am Coll Cardiol 2009;53:849-56
Baseline Characteristics of the Study Population Sibbing D, et al. J Am Coll Cardiol 2009;53:849-56
Angiographic and Procedural Characteristics Sibbing D, et al. J Am Coll Cardiol 2009;53:849-56
Characteristics of Patients With Definite or Probable ST Sibbing D, et al. J Am Coll Cardiol 2009;53:849-56
Kaplan-Meier analysis for the cumulative incidence of stent thrombosis (A) and for the composite of death or stent thrombosis (B) Sibbing D, et al. J Am Coll Cardiol 2009;53:849-56
Distribution of ST Across Quintiles Sibbing D, et al. J Am Coll Cardiol 2009;53:849-56
Clinical Outcome Sibbing D, et al. J Am Coll Cardiol 2009;53:849-56
Baseline Characteristics According to CET Rate Marianne Zeller, et al. J Am Coll Cardiol 2007;50:
Literature Search Strategy Used for the MEDLINE Database Gami AS, et al. J Am Coll Cardiol 2007;49:
Five year clinical follow-up of the PASSION-trial Five year clinical follow-up of the PASSION-trial Five Year Follow-up after Primary PCI with a Paclitaxel-Eluting.
The EMERALD Trial Diabetic Substudy. EMERALD Diabetic Analysis To compare myocardial perfusion and infarct sizes in diabetic and non-diabetic patients.
Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]
Montalescot G, et al. Lancet 2009;373: Trial profile Montalescot G, et al. Lancet 2009;373:
STENT THROMBOSIS: WHICH IMPACT IN REAL CLINICAL PRACTICE? Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino Ospedale S. Giovanni Battista.
Flow diagram showing study population of Chinese patients with type 2 diabetes mellitus and reasons for exclusion Yang X et al. CMAJ 2008;179:
The Influence of Radial vs. Femoral Access on Acute Blood Loss in Patients Undergoing Percutaneous Coronary Intervention Amit Nanda 1, Amit P. Amin 2,
Coronary Revascularisation in Patients With Diabetes Mellitus Dr Rod Stables The Cardiothoracic Centre Liverpool UK.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130 250 mg/dL following up to 8-week washout and 8-week.
FFR vs Angiography for Multivessel Evaluation
FAME 2 year Objective:To investigate the 2-year outcome of PCI guided by FFR in patients with multivessel CAD. Study:Multicenter, single blind, randomized.
Five-Year Follow-up of Safety and Efficacy of the Resolute Zotarolimus-Eluting Stent: Insights from the RESOLUTE Global Clinical Trial Program in Approximately.
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,
2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.
Unrestricted Use of Drug-Eluting Stents Compared with Bare-Metal Stents in Routine Clinical Practice: Findings From the National Heart, Lung, and Blood.
Masoudi FA et al J Am Coll Cardiol (Published online 27 November 2008) CVN Weekly Interventional Update December 8, 2008 Jeffrey J. Popma and Christopher.
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.
© 2018 SlidePlayer.com Inc. All rights reserved.